3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Conditions
Carcinoma, Non-Small-Cell Lung
26
Melanoma
18
Neoplasm Metastasis
14
Neoplasms
12
Squamous Cell Carcinoma of Head and Neck
10
Recurrence
9
Ovarian Neoplasms
7
Skin Neoplasms
6
Head and Neck Neoplasms
5
Carcinoma, Squamous Cell
5
Carcinoma, Renal Cell
5
Carcinoma, Basal Cell
5
Triple Negative Breast Neoplasms
4
Fallopian Tube Neoplasms
4
Breast Neoplasms
4
Uterine Cervical Neoplasms
3
Urinary Bladder Neoplasms
3
Stomach Neoplasms
3
Prostatic Neoplasms
3
Multiple Myeloma
3
Endometrial Neoplasms
3
Colorectal Neoplasms
3
Colonic Neoplasms
3
Carcinoma, Merkel Cell
3
Adenocarcinoma
3
Sarcoma
2
Pancreatic Neoplasms
2
Lymphoma
2
Lung Neoplasms
2
Glioma
2
Interventions
Pemetrexed
9
Carboplatin
7
pembrolizumab
6
Cisplatin
6
130-nm albumin-bound paclitaxel
6
Paclitaxel
5
Nivolumab
5
Gemcitabine
5
palbociclib
4
napabucasin
4
durvalumab
4
Fulvestrant
4
Bevacizumab
4
ribociclib
3
osimertinib
3
abemaciclib
3
Mitomycin
3
Irinotecan
3
Fluorouracil
3
Drug Therapy
3
Anastrozole
3
Albumin-Bound Paclitaxel
3
selpercatinib
2
pralsetinib
2
patritumab
2
ficlatuzumab
2
exemestane
2
atezolizumab
2
Watchful Waiting
2
Trabectedin
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
INDUSTRY
×
Neoplasms by Site
×
cemiplimab
×
Clear all
NCT06463665
2026-06-04
VIRO-25
Genelux Corporation
Phase 2
Recruiting
142 enrolled